Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

CorMedix Inc.

CIK 1410098 CRMD·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Material weakness 10-K
  2. Auditor change 8-K +118d
  3. Accounting standard newly cited 10-Q +43d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Accounting standard newly cited Filing comparison

CorMedix Inc. cited accounting standard ASU 2025-10 for the first time in this filing series

Recent Accounting Pronouncements Effective January 1, 2026, the Company early adopted ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities.
Evidence
Adopted
2025-10
Adoption year stated
2026
Contexts
Recent Accounting Pronouncements Effective January 1, 2026, the Company early adopted ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities.
New standards
2024-03, 2025-05, 2025-10, 2025-11
Prior filed
2026-05-14
Prior form
10-Q
Restates existing policy
No
Source
accounting standards update (ASU) reference comparison
Why
The summary of significant accounting policies changed materially from the previous comparable filing.

Source filing ↗ Prior filing ↗

Auditor change SEC item code

CorMedix Inc. reported a change in its independent accounting firm

The company dismissed the auditor. CBIZ → not stated

Evidence
Direction
dismissed
Direction label
The company dismissed the auditor
Item code
4.01
Item title
Changes in Registrant's Certifying Accountant
Predecessor auditor
CBIZ
Predecessor tier
national
Severity
normal
Source
SEC 8-K item code
Why
The company's independent registered accounting firm changed.

Source filing ↗

Material weakness high Filing comparison

CorMedix Inc. reported a material weakness in internal control

Internal control reported effective → Material weakness in internal control

Based on the material weakness described above, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our Chief Executive…
Evidence
Current state
material_weakness
Current state label
Material weakness in internal control
Direction
newly reported
Prior filed
2025-03-25
Prior form
10-K
Prior state
effective
Prior state label
Internal control reported effective
Remediation stated
Yes
Severity
high
Source
Item 9A internal control conclusion, compared with the prior filing
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗